The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Rollover study for patients who received CP-675,206 in other protocols, to allow the patients access to CP-675,206 until this agent becomes commercially available or development is discontinued
- collapse Clinical study assessing the safety, tolerability, and pharmacokinetics of intravenous AZD5099 in health subjects
- collapse A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia
- collapse A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
- collapse A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
- collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)
- collapse Observational retrospective Study to Describe the Management of Advanced or Metastatic EGFR Mutated Non-small Cell Lung Cancer Patients in Spain.
- collapse A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies
- collapse Tolerability,Pharmacokinetics&Preliminary Antitumour Activity of Ascending Doses of AZD9291 in Patients With Advanced Non Small Cell LungCancer Who Have Progressed Following Prior Therapy With an Epidermal Growth FactorReceptorTyrosineKinaseInhibatoragent
- collapse A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer (ACT-FASTER:)
